Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy
2007-002088-29Phase 3Completed
- Sponsor
- Rheoscience
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of balaglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Rheoscience. Primary endpoint: Change in HbA1c (Balaglitazone vs Placebo). Started May 2007; status: completed.
02
Drugs
balaglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002088-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002088-29.